Heavily pretreated patients with metastatic breast cancer characterized by a high tumor mutational burden are likely to derive “meaningful clinical benefit” from pembrolizumab monotherapy, say the TAPUR researchers.
Individuals with breast cancer and a BRCA1/2 variant experience comparable survival rates whether they are treated with breast-conserving therapy or mastectomy with or without radiotherapy, Chinese researchers suggest.
The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.
Women with hormone receptor-positive, HER2-negative metastatic breast cancer derive a significant progression-free survival benefit from the addition of alisertib to paclitaxel, indicate phase 2 trial findings.
An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.